Nanoemulsion improves the oral bioavailability of baicalin in rats: In vitro and in vivo evaluation

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3769-3779

  Zhao, Ling ^a   Wei, Yumeng ^a   Huang, Yu ^a   He, Bing ^a   Zhou, Yang ^a   Fu, Junjiang ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Baicalin; Nanoemulsion; Oral bioavailability; Pharmacokinetics

Indexed keywords

BAICALEIN; BAICALIN; MACROGOL 400; MYRISTIC ACID ISOPROPYL ESTER; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; RUTOSIDE; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DILUTION; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOEMULSION; NONHUMAN; RAT; SUSPENSION; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY;

BAICALIN; NANOEMULSION; ORAL BIOAVAILABILITY; PHARMACOKINETICS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; EMULSIONS; FLAVONOIDS; MALE; METABOLIC CLEARANCE RATE; MOUTH; NANOCAPSULES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84885070935     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51578     Document Type: Article

References (38)

1. Boyle SP, Doolan PJ, Andrews CE, Reid RG. Evaluation of quality control strategies in Scutellaria herbal medicines. J Pharm Biomed Anal. 2011;54(5):951-957.
2. Franek KJ, Zhou Z, Zhang WD, Chen WY. In vitro studies of baicalin alone or in combination with Salvia miltiorrhiza extract as a potential anti-cancer agent. Int J Oncol. 2005;26(1):217-224.
3. Mao W, Chen X, Yang T, etal. A rapid fluorescent screening method for cellular sensitivity to anti-cancer compound. Cytotechnology. 2012; 64(4):451-457.
4. Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica. 2010;40(5):357-367.
5. Huang Y, Tsang SY, Yao X, Chen ZY. Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Hematol Disord. 2005;5(2):177-184.
6. Li B, Wen M, Li W, He M, Yang X, Li S. Preparation and characterization of baicalin-poly-vinylpyrrolidone coprecipitate. Int J Pharm. 2011;408(1-2):91-96.
7. Taiming L, Xuehua J. Investigation of the absorption mechanisms of baicalin and baicalein in rats. J Pharm Sci. 2006;95(6):1326-1333.
8. Xing J, Chen X, Sun Y, Luan Y, Zhong D. Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract. J Pharm Pharmacol. 2005;57(6):743-750.
9. Xing J, Chen X, Zhong D. Absorption and enterohepatic circulation of baicalin in rats. Life Sci. 2005;78(2):140-146.
10. Zheng WW, Zhao L, Wei YM, Ye Y, Xiao SH. Preparation and the in vitro evaluation of nanoemulsion system for the transdermal delivery of granisetron hydrochloride. Chem Pharm Bull. 2010;58(8):1015-1019.
11. Ryu JK, Yoo SD. Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability. Drug Dev Ind Pharm. 2012;38(11):1313-1318.
12. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS Pharm Sci Tech. 2009;10(3):808-819.
13. Bali V, Ali M, Ali J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids Surf B Biointerfaces. 2010;76(2):410-420.
14. Kuminek G, Kratz JM, Ribeiro R, etal. Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs. Int J Pharm. 2009; 378(1-2):146-148.
15. Kuo F, Kotyla T, Wilson T, etal. A nanoemulsion of an anti-oxidant synergy formulation reduces tumor growth rate in neuroblastoma-bearing nude mice. J Exp Ther Oncol. 2007;6(2):129-135.
16. Singh KK, Vingkar SK. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm. 2008;347(1-2):136-143.
17. Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 2009;6(3):928-939.
18. Vyas TK, Shahiwala A, Amiji MM. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm. 2008;347(1-2):93-101.
19. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561-1572.
20. Yong CS, Park BJ, Kim DH, etal. Short communication: in vivo evaluation of microemulsion system for oral and parenteral delivery of rutaecarpine to rats. Drug Dev Ind Pharm. 2007;33(5):531-534.
21. Hirunpanich V, Sato H. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient. Eur J Pharm Biopharm. 2009;73(2):247-252.
22. Wu H, Lu C, Zhou A, Min Z, Zhang Y. Enhanced oral bioavailability of puerarin using microemulsion vehicle. Drug Dev Ind Pharm. 2009;35(2):138-144.
23. Yin YM, Cui FD, Mu CF, etal. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release. 2009;140(2):86-94.
24. Attivi D, Ajana I, Astier A, Demoré B, Gibaud S. Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm. 2010;36(4):421-427.
25. He CX, He ZG, Gao JQ. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. Expert Opin Drug Deliv. 2010;7(4):445-460.
26. Hu L, Wu H, Niu F, Yan C, Yang X, Jia Y. Design of fenofibrate microemulsion for improved bioavailability. Int J Pharm. 2011; 420(2):251-255.
27. Kovarik JM, Mueller EA, van Bree JB, Arns W, Renner E, Kutz K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit. 1994;16(3):232-237.
28. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 1994;11(2):301-304.
29. Mandal S, Mandal SS, Surti N, Patel VB. Design and development of saquinavir microemulsion for the oral bioavailability. Pharm Tech Res. 2009;1:1442-1448.
30. Hugen PW, Burger DM, Koopmans PP, etal. Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast. Pharm World Sci. 2002;24(3):83-86.
31. Fatouros DG, Karpf DM, Nielsen FS, Mullertz A. Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther Clin Risk Manag. 2007;3(4):591-604.
32. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66(2):227-243.
33. Chen H, Zhong YQ, Lu Y. Preparation of puerarin by microemulsion drug delivery system. Journal of Pharmaceutical Practice. 2008;3:200-203. Chinese.
34. Nepal PR, Han HK, Choi HK. Preparation and in vitro-in vivo evaluation of Witepsol H35 based self-nanoemulsifying drug delivery systems (SNEDDS) of coenzyme Q(10). Eur J Pharm Sci. 2010; 39(4):224-232.
35. Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15(21-22):958-965.
36. Tang SY, Manickam S, Wei TK, Nashiru B. Formulation development and optimization of a novel Cremophore EL-based nanoemulsion using ultrasound cavitation. Ultrason Sonochem. 2012;19(2):330-345.
37. Kelmann RG, Kuminek G, Teixeira HF, Koester LS. Carbamazepine parenteral nanoemulsions prepared by spontaneous emulsification process. Int J Pharm. 2007;342(1-2):231-239.
38. Hao J, Wang F, Wang X, etal. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eur J Pharm Sci. 2012;47(2): 497-505.